{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiah6wn5dnxipiwcytczqldy36kvxumd5yvmj5h7euuwh56cx2nksm",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mlhezvucdjd2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifgypwrvif5xqxubgx5qk7pugjvikiwamz6bdrzrqvh4yq6oc7mfa"
    },
    "mimeType": "image/jpeg",
    "size": 530784
  },
  "path": "/news/2026-05-benefits-obesity-linked-conditions-weight.html",
  "publishedAt": "2026-05-09T18:00:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "New research presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) shows that, following treatment for obesity or diabetes or both, using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to a relatively lower risk of obesity-related conditions. The study is by Professor John Wilding of the University of Liverpool, UK, and colleagues.",
  "title": "Study shows benefits in obesity-linked conditions of losing more weight with GLP-1 treatment"
}